
High-performance liquid chromatography (HPLC) confirms safe blood levels of slow-release bupivacaine nanoparticles.
Earlier assessment of molecules provides valuable insights into the manufacturing developability of molecules, reducing the need for unnecessary experimentation. The Intabio ZT system has the potential to make in-depth characterization of biopharmaceutical product charge variants quicker and more efficient to meet demanding timelines during early-phase clinical development.





